Does USTEKINUMAB Cause Basal cell carcinoma? 500 Reports in FDA Database
Visibly Younger Skin in Weeks
Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 500 reports of Basal cell carcinoma have been filed in association with USTEKINUMAB (PYZCHIVA). This represents 0.6% of all adverse event reports for USTEKINUMAB.
500
Reports of Basal cell carcinoma with USTEKINUMAB
0.6%
of all USTEKINUMAB reports
1
Deaths
177
Hospitalizations
How Dangerous Is Basal cell carcinoma From USTEKINUMAB?
Of the 500 reports, 1 (0.2%) resulted in death, 177 (35.4%) required hospitalization, and 2 (0.4%) were considered life-threatening.
Is Basal cell carcinoma Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for USTEKINUMAB. However, 500 reports have been filed with the FAERS database.
What Other Side Effects Does USTEKINUMAB Cause?
Drug ineffective (12,471)
Off label use (10,990)
Product dose omission issue (9,405)
Fatigue (5,457)
Product use issue (5,008)
Psoriasis (4,955)
Pain (4,872)
Rash (4,736)
Crohn's disease (4,662)
Arthralgia (4,608)
What Other Drugs Cause Basal cell carcinoma?
ADALIMUMAB (1,547)
INFLIXIMAB (1,340)
METHOTREXATE (1,268)
RITUXIMAB (1,085)
ETANERCEPT (998)
ABATACEPT (852)
TOCILIZUMAB (761)
LENALIDOMIDE (685)
HYDROXYCHLOROQUINE (662)
LEFLUNOMIDE (657)
Which USTEKINUMAB Alternatives Have Lower Basal cell carcinoma Risk?
USTEKINUMAB vs USTEKINUMAB-STBA
USTEKINUMAB vs VADADUSTAT
USTEKINUMAB vs VALACYCLOVIR
USTEKINUMAB vs VALBENAZINE
USTEKINUMAB vs VALBENAZINE DITOSYLATE